CANYON PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.canyonpharma.com
Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Canyon Pharmaceuticals, Inc.
- Target Recruit Count
- 516
- Registration Number
- NCT00913133
- Locations
- 🇺🇸
Saint Joseph's Research Institute, Atlanta, Georgia, United States
🇺🇸The Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome
Phase 4
Terminated
- Conditions
- Suspected Heparin-Induced Thrombocytopenia
- Interventions
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Canyon Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00787332
- Locations
- 🇺🇸
Maine Medical Center, Portland, Maine, United States
🇺🇸North Shore University Hospital, Manhasset, New York, United States
🇺🇸University of South Florida, Tampa General Hospital, Tampa, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath